<DOC>
	<DOCNO>NCT00938275</DOCNO>
	<brief_summary>The primary objective study assess pharmacokinetic profile single 500 mg dose SRT2104 administer oral suspension capsule formulation normal healthy male female volunteer feed fasted state . The secondary objective ass safety tolerance SRT2104 administer oral suspension capsule formulation healthy male female volunteer feed fasted state .</brief_summary>
	<brief_title>A Clinical Study Assess Effect Food Gender Pharmacokinetics SRT2104 Administered Oral Suspension Capsule Formulation Normal Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Be healthy male female within age range 18 55 year . Voluntarily sign Research Ethics Committee ( REC ) approve informed consent form participate study relevant aspect study explain discuss subject . Have Hematology , Coagulation , Clinical Chemistry Urinalysis test result within normal , allowable limit ( outofrange , must consider clinically significant exclusionary ) perform within 21 day receive first dose test material . Have BMI ( Body Mass Index ) 18.0 30.0 kg/m^2 . Be clear history HIV hepatitis B C. Have significant disease clinically significant abnormal laboratory value deem investigator laboratory evaluation , medical history , physical exam . Have normal 12lead ECG ECG abnormality consider clinically insignificant . Have ability communicate investigative site staff manner sufficient carry protocol procedure describe . All subject partner must agree use acceptable double barrier method birth control Screening visit 3 month last dose test material . All female subject must nonchildbearing potential . For purpose study , define subject amenorrheic least 12 consecutive month least 6 week postsurgical bilateral oophorectomy without hysterectomy . ( Menopausal status confirm demonstrating level follicle stimulate hormone ( FSH ) 20 138 mIU/ml oestradiol &lt; 20 pg/ml entry . In event subject 's menopause status clearly establish ( example , subject indicate amenorrheic 10 year ) , FSH and/or oestradiol level consistent postmenopausal condition , determination subject eligibility discretion principal investigator follow consultation sponsor . Subject agree refrain consumption grapefruit and/or grapefruit juice 7 day prior day 1 treatment visit 1 end subject 's final study visit . Subject major illness past three month significant ongoing chronic medical illness Investigator would deem unfavorable enrollment . Subject renal liver impairment . Subject history gastrointestinal surgery current gastrointestinal disease may influence drug absorption . Subject history , within 3 year , drug abuse ( include Benzodiazepines , opioids , amphetamine , cocaine , THC ) positive drug result Screening . Subject smoke 5 cigarette day . Subject history alcoholism , and/or currently drink three drink per day [ one drink equal one unit alcohol ( one glass wine , half pint beer , one measure spirit ) ] . Subject participate clinical trial within past three month ( define three month date last dose investigational medicinal product ) . Subject history difficulty donate blood accessibility vein leave right arm . Subject donate blood ( one unit 350 mL ) within three month prior receive test material . Subject take herbal product , overthecounter medication prescription drug therapy ( exception hormone replacement therapy female subject ) 5 time halflife longer 21 day ( i.e. , Screening period ) prior enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>